OptiBiotix Health Plc (OPBXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OptiBiotix Health Plc (OPBXF) trades at $0.22 with AI Score 43/100 (Grade C). OptiBiotix Health Plc researches and develops microbiome modulators. Market cap: $20.06M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for OPBXF: OPBXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OPBXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OPBXF: the 1 perspectives are evenly split.
How is this calculated? →OptiBiotix Health Plc (OPBXF) Healthcare & Pipeline Overview
OptiBiotix Health Plc, a life sciences company, focuses on developing microbiome modulators for food ingredients and supplements. Their product portfolio targets chronic lifestyle diseases, offering solutions for weight management, cholesterol control, and overall wellbeing, positioning them within the competitive biotechnology sector.
What Is the Investment Thesis for OPBXF?
OptiBiotix Health Plc presents a focused investment opportunity within the microbiome modulation sector. The company's diverse product portfolio, targeting prevalent chronic diseases, offers potential for revenue growth. Key value drivers include the expansion of SlimBiome and CholBiome product lines, alongside the development of novel microbial strains. The company's gross margin of 36.5% indicates potential for profitability as revenue scales. However, the negative P/E ratio of -34.31 and a negative profit margin of -16.6% highlight existing financial challenges. Upcoming catalysts include potential partnerships and regulatory approvals for new products. Potential risks include competition from established players and the need for further funding to support research and development.
Based on FMP financials and quantitative analysis
OPBXF Key Highlights
- Market capitalization of $20.06M, indicating a small-cap company with potential for growth.
- Gross margin of 36.5%, reflecting the company's ability to generate revenue efficiently from its products.
- Beta of 1.75, suggesting higher volatility compared to the market, which may appeal to risk-tolerant investors.
- Focus on microbiome modulators, a growing area of interest in the healthcare and food industries.
- Product portfolio targeting chronic lifestyle diseases, addressing a significant market need.
Who Are OPBXF's Competitors?
OPBXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.47M | 46 |
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.35M | 46 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.73M | 44 |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.12M | 42 |
| KMSTF Kadimastem Ltd | $3.21 | -3.02% | $9.50M | 44 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPBXF's Key Strengths?
- Proprietary microbiome modulation technology.
- Diverse product portfolio targeting chronic diseases.
- Scientific expertise and research capabilities.
What Are OPBXF's Weaknesses?
- Negative profitability and reliance on external funding.
- Limited market presence compared to larger competitors.
- Dependence on regulatory approvals for product commercialization.
What Could Drive OPBXF Stock Higher?
- Expansion of SlimBiome product line into new markets.
- Development of novel microbial strains for various applications.
- Strategic partnerships and collaborations with food manufacturers.
- Regulatory approvals for products in key markets.
- Focus on personalized nutrition and tailored solutions.
What Are the Key Risks for OPBXF?
- Negative return on equity (-52.9%) — the business is not currently generating profit on shareholder capital.
- Competition from established players in the biotechnology industry.
- Regulatory changes and compliance requirements.
- Patent expiration and intellectual property challenges.
- Negative profitability and reliance on external funding.
- Limited market presence compared to larger competitors.
What Are the Growth Opportunities for OPBXF?
- Expansion of SlimBiome Product Line: SlimBiome, a natural ingredient for weight management, presents a significant growth opportunity. The global weight management market is estimated to be worth billions of dollars, with increasing consumer demand for natural and effective solutions. OptiBiotix can leverage this trend by expanding its SlimBiome product line, targeting new markets, and developing innovative formulations. Timeline: Ongoing.
- Development of Novel Microbial Strains: OptiBiotix's research and development efforts in identifying and developing novel microbial strains offer substantial growth potential. These strains can be used in various applications, including food ingredients, supplements, and active compounds. Successful development and commercialization of new strains can lead to increased revenue and market share. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with food manufacturers, supplement companies, and pharmaceutical firms can accelerate OptiBiotix's growth. These partnerships can provide access to new markets, distribution channels, and technological expertise. Collaborations can also facilitate the development and commercialization of new products. Timeline: Ongoing.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals for its products in key markets is crucial for OptiBiotix's growth. These approvals can enhance the credibility and market acceptance of its products. Expanding market access through strategic partnerships and distribution agreements can further drive revenue growth. Timeline: Ongoing.
- Focus on Personalized Nutrition: The growing trend of personalized nutrition presents an opportunity for OptiBiotix to develop tailored microbiome solutions for individual consumers. By leveraging data analytics and microbiome profiling, the company can create personalized products and services that address specific health needs. This approach can enhance customer engagement and loyalty. Timeline: Ongoing.
What Opportunities Does OPBXF Have?
- Expanding market for microbiome-based products.
- Strategic partnerships and collaborations.
- Personalized nutrition and tailored solutions.
What Threats Does OPBXF Face?
- Competition from established players.
- Regulatory changes and compliance requirements.
- Patent expiration and intellectual property challenges.
What Are OPBXF's Competitive Advantages?
- Proprietary microbial strains and formulations.
- Intellectual property protection through patents.
- Scientific expertise in microbiome modulation.
What Does OPBXF Do?
Founded in 2012 and headquartered in York, United Kingdom, OptiBiotix Health Plc is a life sciences company dedicated to the research and development of microbiome modulators. The company identifies and cultivates microbial strains, compounds, and formulations designed for integration into food ingredients, supplements, and active compounds. These products aim to positively influence human physiology and deliver potential health benefits. OptiBiotix's product line includes Slimbiome, a natural ingredient for weight management; SlimBiome Medical, a weight management supplement; CholBiome, a supplement for maintaining healthy cholesterol levels; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health; LPGOS, a galactooligosaccharide used in food applications to reduce cardiovascular risk factors; WellBiome, a functional fiber and mineral blend promoting gut microbiome diversity; and Sweetbiotix, a sweetener for food and beverages. The company's strategic focus is on preventing and managing chronic lifestyle diseases, such as obesity, hypercholesterolemia, and diabetes, through innovative microbiome modulation technologies.
What Products and Services Does OPBXF Offer?
- Researches and develops microbiome modulators.
- Identifies and develops microbial strains.
- Creates compounds and formulations for food ingredients.
- Develops supplements with potential health benefits.
- Offers solutions for weight management.
- Provides products for maintaining healthy cholesterol levels.
- Develops sweeteners for food and beverages.
How Does OPBXF Make Money?
- Develops and patents proprietary microbial strains and formulations.
- Sells ingredients and supplements to food manufacturers and consumers.
- Generates revenue through licensing agreements and product sales.
What Industry Does OPBXF Operate In?
OptiBiotix Health Plc operates within the biotechnology industry, specifically focusing on microbiome modulation. This sector is experiencing growth due to increasing awareness of the gut microbiome's impact on health. The competitive landscape includes companies developing probiotics, prebiotics, and other microbiome-related products. OptiBiotix differentiates itself through its focus on specific health conditions and its range of proprietary ingredients. The global microbiome market is projected to reach billions of dollars in the coming years, presenting significant opportunities for companies like OptiBiotix.
Who Are OPBXF's Key Customers?
- Food manufacturers seeking innovative ingredients.
- Supplement companies looking to enhance their product offerings.
- Consumers interested in natural health solutions.
OPBXF Valuation & Market Position
With a $20.06M market cap, OptiBiotix Health Plc sits in the micro-cap segment of the market. Relative to its peer group, OPBXF's quantitative score of 43/100 is roughly in line with the peer average of 44/100.
ROE -53%Key Financial Metrics
Return on equity for OptiBiotix Health Plc stands at -52.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -56.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -58.5%, the inverse of the P/E and a quick read on earnings relative to price.
OPBXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary microbiome modulation technology.
- Diverse product portfolio targeting chronic diseases.
- Scientific expertise and research capabilities.
- Ongoing: Expansion of SlimBiome product line into new markets.
Bear Case
- Negative profitability and reliance on external funding.
- Limited market presence compared to larger competitors.
- Dependence on regulatory approvals for product commercialization.
- Potential: Competition from established players in the biotechnology industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OPBXF Latest News
No recent news available for OPBXF.
OPBXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPBXF.
Price Targets
Wall Street price target analysis for OPBXF.
OPBXF MoonshotScore
What does this score mean?
The MoonshotScore rates OPBXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stephen Patrick O'Hara
CEO
Stephen Patrick O'Hara serves as the CEO of OptiBiotix Health Plc. Information regarding his detailed background, career history, education, and previous roles is not available in the provided source data. However, as the CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the microbiome modulation sector.
Track Record: Stephen Patrick O'Hara, as CEO, is responsible for guiding OptiBiotix Health Plc in its research and development of microbiome modulators. Specific achievements, strategic decisions, and company milestones under his leadership are not detailed in the provided source data. He manages a team of 9 employees.
OPBXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that OptiBiotix Health Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. This tier typically includes companies with distressed financials, early-stage ventures, or those that choose not to comply with higher reporting standards. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their experience.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal issues.
- Focus on scientific research and development.
- Development of proprietary technologies.
- Partnerships with reputable organizations.
- Presence of experienced management team.
- Addresses a clear market need in microbiome modulation.
What Investors Ask About OptiBiotix Health Plc (OPBXF) — Healthcare
What does OptiBiotix Health Plc do?
OptiBiotix Health Plc is a life sciences company focused on researching and developing microbiome modulators. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds. These products aim to impact human physiology and provide health benefits, particularly in preventing and managing chronic lifestyle diseases such as obesity, hypercholesterolemia, and diabetes. The company's product line includes Slimbiome, CholBiome, and WellBiome.
What are the main risks for OPBXF?
The main risks for OPBXF include competition from established players in the biotechnology industry, regulatory changes and compliance requirements, and potential patent expiration and intellectual property challenges. The company's negative profitability and reliance on external funding also pose significant risks. Additionally, its limited market presence compared to larger competitors could hinder its growth prospects. Investing in OPBXF carries inherent risks associated with OTC stocks, including limited liquidity and disclosure.
How does OptiBiotix Health Plc manage patent expiration risks?
Due to limited information, it is difficult to assess OptiBiotix Health Plc's specific strategies for managing patent expiration risks. However, as a biotechnology company, it likely employs strategies such as developing new formulations, seeking patent extensions, and creating a pipeline of innovative products to mitigate the impact of patent expirations. Continuous research and development are crucial for maintaining a competitive edge and protecting intellectual property.
What revenue streams does OptiBiotix Health Plc have in healthcare?
OptiBiotix Health Plc generates revenue through the sale of its microbiome modulators, including Slimbiome, CholBiome, and WellBiome. These products are sold as ingredients to food manufacturers and as supplements to consumers. The company also generates revenue through licensing agreements and partnerships with other companies. The specific breakdown of revenue by product line, therapeutic area, and geographic market is not available in the provided source data.
What are the key factors to evaluate for OPBXF?
OptiBiotix Health Plc (OPBXF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does OPBXF data refresh on this page?
OPBXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OPBXF's recent stock price performance?
OptiBiotix Health Plc (OPBXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary microbiome modulation technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPBXF overvalued or undervalued right now?
Valuing OptiBiotix Health Plc (OPBXF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- AI analysis pending for OPBXF.